Immunogenicity of Inovio SARS-CoV-2 Vaccine candidate in Ferrets. (Old ID 27533)

Chief Investigator

This project aims to characterise the immune responses following two doses of SARS-CoV-2 vaccine candidates produced by Inovio Pharmaceuticals. The Inovio vaccine candidates are DNA-based vaccines (as opposed to RNA-based, such as the Pfizer vaccine; or viral vector-based, such as the AstraZeneca vaccine) and rely upon the injection of a circular DNA (plasmid) that, when it gets into a cell, tells the cell to produce a particular protein from SARS-CoV-2 (in this case the Spike protein, found on the surface of the virus particle). Completion of these studies will further support the Inovio vaccine candidate along its pathway to licensure for use in humans, in the context of emerging variants of concern, thus aiding in the testing of a vaccine that may be used to protect humans from SARS-CoV-2 infection in the future.

11 Feb 2022 - 30 Jun 2022

N/A